These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 2137978)

  • 1. Effects of nafarelin on bone density.
    Jacobson JB
    Am J Obstet Gynecol; 1990 Feb; 162(2):591-2. PubMed ID: 2137978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of a gonadotropin-releasing hormone agonist analog (nafarelin) on bone metabolism.
    Johansen JS; Riis BJ; Hassager C; Moen M; Jacobson J; Christiansen C
    J Clin Endocrinol Metab; 1988 Oct; 67(4):701-6. PubMed ID: 2971080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increases in bone mineral density after discontinuation of daily human parathyroid hormone and gonadotropin-releasing hormone analog administration in women with endometriosis.
    Finkelstein JS; Arnold AL
    J Clin Endocrinol Metab; 1999 Apr; 84(4):1214-9. PubMed ID: 10199756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is it possible to prevent bone loss in young women treated with luteinizing hormone-releasing hormone agonists?
    Riis BJ; Christiansen C; Johansen JS; Jacobson J
    J Clin Endocrinol Metab; 1990 Apr; 70(4):920-4. PubMed ID: 2138631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduction of bone mineral density by gonadotropin-releasing hormone agonist, nafarelin, is not completely reversible at 6 months after the cessation of administration.
    Taga M; Minaguchi H
    Acta Obstet Gynecol Scand; 1996 Feb; 75(2):162-5. PubMed ID: 8604604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of nafarelin and danazol on vertebral trabecular bone mass in patients with endometriosis.
    Whitehouse RW; Adams JE; Bancroft K; Vaughan-Williams CA; Elstein M
    Clin Endocrinol (Oxf); 1990 Sep; 33(3):365-73. PubMed ID: 2147597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gonadotropin-releasing hormone analogs: update on new findings.
    Henzl MR
    Am J Obstet Gynecol; 1992 Feb; 166(2):757-61. PubMed ID: 1531579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hormonal Add-Back Therapy for Females Treated With Gonadotropin-Releasing Hormone Agonist for Endometriosis: A Randomized Controlled Trial.
    DiVasta AD; Feldman HA; Sadler Gallagher J; Stokes NA; Laufer MR; Hornstein MD; Gordon CM
    Obstet Gynecol; 2015 Sep; 126(3):617-627. PubMed ID: 26181088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in vitamin D metabolism during natural and medical menopause.
    Hartwell D; Riis BJ; Christiansen C
    J Clin Endocrinol Metab; 1990 Jul; 71(1):127-32. PubMed ID: 2142491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence of similar increases in bone turnover during nafarelin and danazol use in women with endometriosis.
    Ylikorkala O; Nilsson CG; Hirvonen E; Viinikka L
    Gynecol Endocrinol; 1990 Dec; 4(4):251-60. PubMed ID: 2150580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of a gonadotropin-releasing hormone agonist on the calcium-parathyroid axis and bone turnover in women with endometriosis.
    Newhall-Perry K; Holloway L; Osburn L; Monroe SE; Heinrichs L; Henzl M; Marcus R
    Am J Obstet Gynecol; 1995 Sep; 173(3 Pt 1):824-9. PubMed ID: 7573251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of nafarelin versus danazol on lipids and calcium metabolism.
    Bergquist C
    Am J Obstet Gynecol; 1990 Feb; 162(2):589-91. PubMed ID: 2137977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic efficacy and bone mineral density response during and following a three-month re-treatment of endometriosis with nafarelin (Synarel).
    Adamson GD; Heinrichs WL; Henzl MR; Yuzpe AA; Bergquist C; Jacobson JJ; Eriksson S; Kwei L; Gilbert SM
    Am J Obstet Gynecol; 1997 Dec; 177(6):1413-8. PubMed ID: 9423744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nafarelin therapy in endometriosis: long-term effects on bone mineral density.
    Orwoll ES; Yuzpe AA; Burry KA; Heinrichs L; Buttram VC; Hornstein MD
    Am J Obstet Gynecol; 1994 Nov; 171(5):1221-5. PubMed ID: 7977523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized double blind placebo controlled trial of the effects on bone metabolism of the combination of nafarelin acetate and norethisterone.
    Eldred JM; Haynes PJ; Thomas EJ
    Clin Endocrinol (Oxf); 1992 Oct; 37(4):354-9. PubMed ID: 1483292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of endometriosis with a decreasing dosage of a gonadotropin-releasing hormone agonist (nafarelin): a pilot study with low-dose agonist therapy ("draw-back" therapy).
    Tahara M; Matsuoka T; Yokoi T; Tasaka K; Kurachi H; Murata Y
    Fertil Steril; 2000 Apr; 73(4):799-804. PubMed ID: 10731543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Administration of nasal nafarelin as compared with oral danazol for endometriosis. A multicenter double-blind comparative clinical trial.
    Henzl MR; Corson SL; Moghissi K; Buttram VC; Berqvist C; Jacobson J
    N Engl J Med; 1988 Feb; 318(8):485-9. PubMed ID: 2963213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nafarelin acetate: a gonadotropin-releasing hormone agonist for the treatment of endometriosis.
    Letassy NA; Thompson DF; Britton ML; Suda RR
    DICP; 1990 Dec; 24(12):1204-9. PubMed ID: 2151003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nafarelin: a new medical therapy for endometriosis.
    Henzl MR; Monroe SE
    Prog Clin Biol Res; 1990; 323():343-55. PubMed ID: 2137620
    [No Abstract]   [Full Text] [Related]  

  • 20. Efficacy and safety of nafarelin in the treatment of endometriosis.
    Henzl MR; Kwei L
    Am J Obstet Gynecol; 1990 Feb; 162(2):570-4. PubMed ID: 2137971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.